Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 4/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CDK2AP1 | O14519 | 3/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6397671 | 0.94 | LMNA (0.46) | LMNAKDRTHRBTP53BRD4 | |
| SCHEMBL6094904 | 0.90 | KDM1A (0.46) | LMNAKDRTHRBTP53BRD4 | |
| SCHEMBL6094557 | 0.89 | LMNA (0.44) | LMNAKDRTHRBTP53BRD4 | |
| SCHEMBL6094530 | 0.89 | MCHR1 (0.42) | LMNATHRBTP53MCHR1NR1H4 | |
| SCHEMBL7367184 | 0.86 | BRD4 (0.48) | LMNATHRBTP53BRD4CREBBP | |
| SCHEMBL6093368 | 0.86 | LMNA (0.45) | LMNATHRBTP53BRD4CREBBP | |
| SCHEMBL6094240 | 0.86 | MAOB (0.45) | LMNATHRBTP53BRD4CREBBP | |
| SCHEMBL6095650 | 0.85 | LMNA (0.44) | LMNATHRBTP53MAOBNR1H4 | |
| SCHEMBL6092881 | 0.85 | THRB (0.45) | LMNATHRBTP53BRD4CREBBP | |
| SCHEMBL6095781 | 0.84 | THRB (0.42) | LMNATHRBTP53BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014939-A1 | Fused pyrrolecarboxamides: GABA brain receptor ligands | NEUROGEN CORPORATION | 2005-01-20 | — | — | US | claimed |
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2003-08-14 | — | — | US | claimed |
| US-20010029299-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | NEUROGEN | 2001-10-11 | — | — | US | claimed |
| US-7109351-B1 | Fused pyrrolecarboxamides; GABA brain receptor ligands | NEUROGEN CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050014939-A1 | Fused pyrrolecarboxamides: GABA brain receptor ligands | NEUROGEN CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2003-08-14 | — | — | US | disclosed |
| US-6515140-B2 | Psychological disorders; sleep disorders; anticonvulsants; cognition activators; drug abruse | NEUROGEN CORPORATION | 2003-02-04 | — | — | US | disclosed |
| US-20010029299-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | NEUROGEN | 2001-10-11 | — | — | US | disclosed |
| US-6211365-B1 | BRAIN DISORDERS | NEUROGEN CORPORATION | 2001-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014939-A1 | Fused pyrrolecarboxamides: GABA brain receptor ligands | GABRB2, GABRB1, GABRB3 | LMNA 1133/4885KDR 2313/4885CHEK1 4430/4885 |
| US-20010029299-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | GABRB1, GABRB3, GABRB2 | LMNA 3196/4885KDR 3570/4885CHEK1 4534/4885 |
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | GABRB1, GABRB3, GABRB2 | LMNA 3033/4885KDR 3491/4885CHEK1 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.